Dasiglucagon for treating severe hypoglycemia in patients with diabetes

  • Expert Rev Clin Pharmacol. 2022 Jul;15(7):799-803. doi: 10.1080/17512433.2022.2103537.
Yongjing Ju  1 ,  Duzhen Zhang  2 ,  Junyi Yang  1
Affiliations
  • 1. Department of Pharmaceutical, Central Hospital of Linyi City, Yishui, Shandong, China.
  • 2. Department Ophthalmology, Central Hospital of Linyi City, Yishui, Shandong, China.
PMID: 35848442 DOI: 10.1080/17512433.2022.2103537
Abstract

Introduction: Diabetic patients are prone to hypoglycemia when treated with Insulin. Dasiglucagon is a water-soluble and ready-to-use glucagon analog developed for treating hypoglycemia in patients with diabetes.

Areas covered: A comprehensive literature search was conducted in PubMed. Key search terms included dasiglucagon and hypoglycemia. The pharmacological characteristics, clinical evidence, and place in therapy of dasiglucagon were reviewed.

Expert opinion: Dasiglucagon is a glucagon analog that is stable in water-soluble formulation. It can increase plasma glucose in a dose-dependent manner. Clinical studies have shown that dasiglucagon rapidly and effectively improved insulin-induced hypoglycemia in patients with diabetes. Dasiglucagon was well tolerated and the common adverse events included nausea and vomiting.

Keywords
dasiglucagon; glucagon; hypoglycemia; insulin treatment; type 1 diabetes.
Products